Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Enzalutamide is a prescription androgen receptor inhibitor used for several forms of prostate cancer. Current U.S. labeling includes castration-resistant prostate cancer, metastatic castration-sensitive prostate cancer, and nonmetastatic castration-sensitive prostate cancer with biochemical recurrence at high risk for metastasis. It is sold as Xtandi in capsule and tablet forms.
read more about enzalutamide ...Enzalutamide acts at several steps in androgen receptor signaling. It competitively blocks androgen binding to the receptor, reduces movement of the activated receptor into the cell nucleus, and interferes with receptor interaction with DNA. These actions reduce androgen-driven prostate cancer cell growth.
Enzalutamide is used for castration-resistant prostate cancer, metastatic castration-sensitive prostate cancer, and high-risk biochemical recurrence of nonmetastatic castration-sensitive prostate cancer. Patients with CRPC or metastatic CSPC also receive a GnRH analog unless they have had bilateral orchiectomy. High-risk biochemical recurrence can be treated with or without a GnRH analog.
The recommended dose is 160 mg by mouth once daily with or without food. Capsules and tablets are swallowed whole with enough water. Capsules are not opened, dissolved, or chewed, and tablets are not cut, crushed, or chewed. Dose changes are used for selected adverse reactions and drug interactions.
Serious concerns include seizures, posterior reversible encephalopathy syndrome, hypersensitivity, ischemic heart disease, falls, fractures, severe swallowing difficulty or choking, and fetal harm. Enzalutamide also has substantial drug interaction potential through CYP enzymes. A seizure during treatment calls for permanent discontinuation under current labeling.
It treats castration-resistant prostate cancer, metastatic castration-sensitive prostate cancer, and selected high-risk biochemical recurrence.
The recommended dose is 160 mg once daily with or without food.
Yes. Seizures have occurred during treatment, and current labeling calls for permanent discontinuation after a seizure.
No. Tablets are swallowed whole and are not cut, crushed, or chewed.
Enzalutamide. https://www.cancer.gov/about-cancer/treatment/drugs/enzalutamide. Date Accessed September 29, 2026.
Enzalutamide: MedlinePlus Drug Information. https://medlineplus.gov/druginfo/meds/a612033.html. Date Accessed September 29, 2026.
FDA Approves Enzalutamide for Non-Metastatic Castration-Sensitive Prostate Cancer With Biochemical Recurrence. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-enzalutamide-non-metastatic-castration-sensitive-prostate-cancer-biochemical-recurrence. Date Accessed September 29, 2026.
Improved Outcomes With Enzalutamide in Biochemically Recurrent Prostate Cancer. https://pubmed.ncbi.nlm.nih.gov/37851874/. Date Accessed September 29, 2026.
XTANDI (Enzalutamide) Prescribing Information. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b129fdc9-1d8e-425c-a5a9-8a2ed36dfbdf. Date Accessed September 29, 2026.